More about

Progressive Familial Intrahepatic Cholestasis

News
July 25, 2024
1 min read
Save

FDA expands Livmarli approval for pruritus in PFIC to infants as young as 12 months

FDA expands Livmarli approval for pruritus in PFIC to infants as young as 12 months

The FDA has updated the label indication for Livmarli for the treatment of cholestatic pruritus in patients with progressive familial intrahepatic cholestasis, expanding the patient population to include infants aged 12 months and older.

News
July 03, 2024
2 min read
Save

Maralixibat improves pruritis, reduces total serum bile acids in all PFIC subtypes

Maralixibat improves pruritis, reduces total serum bile acids in all PFIC subtypes

Maralixibat improved cholestatic pruritis and reduced serum bile acids in pediatric patients with progressive familial intrahepatic cholestasis, regardless of disease genotype, according to data from the MARCH-PFIC trial.

News
March 14, 2024
1 min read
Save

FDA approves Livmarli for pruritus in progressive familial intrahepatic cholestasis

FDA approves Livmarli for pruritus in progressive familial intrahepatic cholestasis

The FDA has approved Mirum Pharmaceuticals’ Livmarli oral solution for treatment of cholestatic pruritus in patients aged 5 years and older with progressive familial intrahepatic cholestasis, according to a company release.

News
November 16, 2023
10 min watch
Save

VIDEO: Treatment with Livmarli yields ‘broad base effects’ across range of PFIC types

VIDEO: Treatment with Livmarli yields ‘broad base effects’ across range of PFIC types

BOSTON — In a Healio video exclusive, Pam Vig, PhD, reports late-breaking data that show Livmarli improved liver health and maintained symptom response over 2 years among pediatric patients with progressive familial cholestasis.

News
June 23, 2023
9 min watch
Save

VIDEO: Livmarli reduces serum bile acids and pruritus in PFIC, Alagille syndrome

VIDEO: Livmarli reduces serum bile acids and pruritus in PFIC, Alagille syndrome

In a Healio video exclusive, Pam Vig, PhD, highlights new data on Livmarli for the treatment of patients with pruritus due to progressive familial intrahepatic cholestasis and Alagille syndrome, which were presented at EASL Congress.

News
June 24, 2021
8 min watch
Save

VIDEO: Progressive familial intrahepatic cholestasis improves with use of novel agent

VIDEO: Progressive familial intrahepatic cholestasis improves with use of novel agent

In a video exclusive, Lorenzo D’Antiga, MD, Pappa Giovanni XXIII Hospital, said Bylvay induced a sustained improvement in cholestasis-related parameters in patients with progressive familial intrahepatic cholestasis.